Clinical Guest Contributors

  1. Too Little Info, Too Much Time Wasted: Feasibility Challenges For Sites 1/27/2026

    Incomplete protocols, lengthy sponsor decision timelines, and uncompensated work plague clinical research sites. Learn why these issues exist and how to address them alongside experts from SCRS and Tufts CSDD.

  2. Will New AI Health Assistants Suggest Clinical Trials To Inquiring Patients? 1/27/2026

    New AI health assistants are now doing even more to help patients make sense of symptoms, diagnoses, and treatment options. What does that mean for the discoverability of clinical trials?

  3. What CROs Do Right Isn't Always Obvious To Research Sites 1/26/2026

    CROs are doing many things right. But it's when that right thing is understood — not just executed — that the impact becomes far greater than compliance alone.

  4. How Gilead Includes Patients Most Affected By HIV In Its PrEP Trials 1/26/2026

    VP of Clinical Development, HIV, Moupali Das shares how the sponsor approaches diverse participant recruitment and enrollment, highlighting the importance of early demographic research and careful, intentional PI selection.

  5. 3 Clinical Research Attorneys Talk 2026 Trends 1/23/2026

    Three life sciences legal experts share what they see happening in the year ahead — and what should remain firmly in the past. 

  6. The "One-Trial" Trap: Why 2026's FDA Efficiency Push Actually Doubles Your Operational Risk 1/22/2026

    When it comes to the FDA's new "one-trial" shift, researcher Johnathon Anderson, Ph.D., warns: Do not confuse efficiency with leniency. Here, Anderson offers three factors to consider when adapting to new FDA trial expectations.

  7. Common Issues And Trends In Clinical Research Vendor Qualification 1/21/2026

    Discover the biggest challenges in vendor qualification, including this one misalignment that affected more than half of surveyed respondents.

  8. "Study Within A Study" Reveals Best Recruitment Strategies For Alzheimer's Trials 1/20/2026

    In this Q&A, Acumen Pharmaceuticals shares findings from its Alzheimer's recruitment study, highlighting what efforts proved the most fruitful.

  9. Endpoints, Procedures, And Deviations Are On The Rise — Why? 1/20/2026

    SCRS Chief Site Success Officer Jimmy Bechtel, MBA, and Tufts CSDD Executive Director Ken Getz, MBA, discuss why they're on the rise explore ways to address, and even accept, them. 

  10. Navigating FDA's New AI Systems: Practical Tips For Regulatory Success 1/19/2026

    AI-assisted reviews are changing FDA submissions. In part two of this series, discover how sponsors can address and even preempt regulatory and legal concerns.